

Eris Lifesciences inks strategic partnership with Natco Pharma to launch Semaglutide in India

24 February 2026 | News

To target Type 2 diabetes management aligning with unmet needs in India's expanding metabolic care landscape



Eris Lifesciences has announced a strategic partnership with Natco Pharma for the commercialisation of Semaglutide in India, reinforcing Eris's commitment to expanding its leadership in the fast-growing diabetes and metabolic care segment.

Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management driven by robust clinical outcomes in glycemic control and weight reduction. With India witnessing a rapidly growing diabetic population and increasing awareness around obesity management, GLP-1 therapies represent a high-growth opportunity within the metabolic segment.

Eris has built a strong and scalable presence in diabetology over the years, supported by a wide specialist reach and deep engagement with endocrinologists, diabetologists and physicians across India. The addition of semaglutide is expected to further strengthen Eris' portfolio in advanced diabetes therapies and enhance its participation in next-generation metabolic treatments.

Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market, paving the way for a launch expected in March 2026. The product will target Type 2 diabetes management aligning with unmet needs in India's expanding metabolic care landscape.